Sep 19, 2019 9:00pm EDT XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)
Apr 29, 2019 5:09pm EDT XORTX Provides Overview and Announces $5 Million Financing to Advance Clinical Trials
Apr 16, 2019 10:55am EDT XORTX Shares Findings of Diabetes Study in Youths Supporting High Uric Acid Advances Kidney Disease Progression
Mar 25, 2019 7:00am EDT XORTX Shares Findings of New Diabetes Study Supporting Uric Acid as an Independent Risk Factor
Mar 12, 2019 10:51am EDT XORTX Signs LOI for Co-Development and Licensing Agreement with Japan’s Teijin Pharma Limited
Jan 28, 2019 7:00am EST XORTX to Present at NobleConXV Noble Capital Markets’ 15th Annual Investor Conference